Sentences with phrase «future efficacy studies»

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Thus, future research on human needs to be conducted to study the efficacy of VCO as rewetting agent on dry eye patient.

«The study results elucidate the molecular mechanisms underlying disease progression in multiple sclerosis models, providing a basis for future clinical trials to determine safety and efficacy of these chemical agents in humans with demyelinating disorders,» says Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomic Sciences at Mount Sinai and senior author of the study.

«The distinct neural markers associated with cognitive performance and GWI revealed in our study can be useful for future research to objectively measure the efficacy of treatments for GWI as well as other brain disorders related to the same neurotransmitter system, like Alzheimer's disease.»

The authors of the current study hypothesize that these previous trials may have inadvertently selected subjects who would be nonresponsive to the medication and conclude that future efficacy trials may require the identification of subgroups of patient populations.

«Future research will focus on optimizing the candidate therapies discovered by our team in this study as well as developing biomarkers that can be used to test the efficacy of other potentially promising drugs,» says Dr. Rothstein

A Houston Methodist team led by Mauro Ferrari, PhD and Jenny Chang, MD has received funding from the U.S. Department of Defense to complete preclinical efficacy studies and a future clinical trial testing a breast cancer precision drug.

While we can not predict the outcome of any future safety or efficacy studies, this decision by FDA allowing clinical research to begin represents a major milestone in allowing us to hopefully provide answers to those critical questions in the future,» Conn said.

The A4 study was designed to evaluate safety, tolerability and efficacy of Solanezumab in older individuals who have normal thinking and memory function but who may be at risk for developing dementia related to Alzheimer's disease (AD) in the future.

Future studies will test and compare the efficacy of imatinib and allosteric compounds in mouse models of breast cancer.

Stress resistance has not been assessed however and so the biological relevance of this finding is currently unknown.32 Several IER trials (75 - 85 % ER on restricted days) in overweight / obese populations have reported reductions in various markers of oxidative stress 37, 41, which in one study was accompanied by a complementary increase in the anti-oxidant uric acid.37 In a direct comparison of IER (75 % ER for two days / week) and CER, both ER strategies displayed equal efficacy in reducing levels of fast - acting advanced oxidation protein products (AOPP) after six months, which displayed a tendency to occur earlier (i.e. at three months) in the IER group.41 Levels of slow - acting (i.e. long term) AOPP tended to decrease in the IER group and increase in the CER group which the authors proposed may have resulted from IER - induced activation of autophagy, a key homeostatic cellular process in which dysfunctional or unnecessary cellular proteins are degraded and recycled.41 On the other hand, a follow - up study using similar IER / CER protocols demonstrated comparable reductions in AOPP in both groups after three months.48 Summary and Future Research Directions

Dr. Bry's systematic program of prevention research has included studies that: 1) search for precursors that differentiate adolescents who will develop conduct or substance use problems from those who will not and environmental factors that might reduce or buffer those precursors; 2) investigate whether these factors actually precede or reduce future problems; and 3) test the outcome efficacy and effectiveness of experimental methods to modify these factors.

The correlation found can be used to guide future interventions with these patients, but the relation should be studied deeper for directional search, if is proved that DM self - efficacy beliefs enhance active coping; self - efficacy based interventions should be promote.

This paper might have suggested the efficacy of certain types of therapy in positively affecting the immune system by way of reducing and managing stress, thus providing direction for future studies.

First, the present study affirmed that positive youth development is comprised of fifteen inter-related constructs, namely, bonding, social competence, emotional competence, cognitive competence, behavioural competence, moral competence, self - efficacy, prosocial norms, resilience, self - determination, spirituality, clear and positive identity, beliefs in the future, prosocial involvement, and recognition for positive behaviour (Catalano et al. 2004), with beliefs in the future having the strongest influence on positive youth development, followed by spirituality (Fig. 6).

In the future, it would be of interest to conduct studies examining the mediating role of academic competency or self - efficacy beliefs among Asian American students.

Since in clinical practice the popularity of mindfulness - based interventions for ADHD is rising, future studies should focus on gathering empirically sound evidence for the efficacy and effectiveness of mindfulness - based interventions, preferably including ratings of independent observers as outcomes.

Future studies should include control beliefs and specific forms of self - efficacy, such as barrier and instrumental self - efficacy.